Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, United States.
Int J Pharm. 2012 May 1;427(1):35-57. doi: 10.1016/j.ijpharm.2011.09.032. Epub 2011 Sep 29.
siRNA based therapeutics is an emerging class of molecules with a high potential for fulfilling the promise of gene medicine. The high selectivity of siRNAs for their targets and subsequent gene ablation has been effectively demonstrated in a wide range of pre-clinical models. siRNA delivery in vivo has been most successfully achieved using lipid-based drug delivery systems. These lipid based formulations are designed to entrap siRNA molecules, ensure stability in in vitro and in vivo milieu, facilitate uptake, enhance cellular targeting, and facilitate delivery in the desired intracellular compartment. As more siRNA-based therapeutics enters the clinic with the associated regulatory scrutiny, there is a clear need to develop well-characterized systems that ensure consistent quality and thus reliable performance. Early clinical trials can be conducted using formulations with limited short-term stability manufactured on a small scale. However, a thorough understanding of the factors that influence the structure and stability of these particulate formulations is required to prevent any issues with optimization of large-scale industrial manufacturing, scale-up, and long-term shelf-life required to support large clinical trials and eventual market use. As newer targets for siRNA are identified and novel lipids are synthesized to optimize their in vivo efficiency, concomitant development of bio-physical methodologies that can improve understanding of the assembly and stability of these complex systems is critical. Along with bio-physical characterization, these assays are also required to reliably design, screen, develop and optimize formulations. Physicochemical characterization thus forms the basis of developing an effective analytical control strategy for siRNA delivery systems. In this review, analytical techniques used to characterize lipid-based siRNA delivery systems are discussed in detail. The importance of these physicochemical characterization techniques and analytical assays is explained. Case studies illustrating their use in siRNA formulation development and optimization are presented.
基于 siRNA 的治疗方法是一类具有很高潜力的新兴分子,有望实现基因医学的承诺。siRNA 对其靶标具有高度选择性,随后导致基因缺失,这在广泛的临床前模型中得到了有效证明。体内 siRNA 的递送最成功地使用了基于脂质的药物递送系统来实现。这些基于脂质的制剂旨在包封 siRNA 分子,确保在体外和体内环境中的稳定性,促进摄取,增强细胞靶向,并促进在所需的细胞内隔室中的递送。随着越来越多的基于 siRNA 的治疗方法进入临床,并伴随着相关的监管审查,显然需要开发具有良好特征的系统,以确保一致的质量,从而实现可靠的性能。早期的临床试验可以使用在小规模上制造的具有有限短期稳定性的制剂进行。然而,需要深入了解影响这些颗粒制剂结构和稳定性的因素,以防止在大规模工业制造、放大和长期货架寿命的优化方面出现任何问题,这些都是支持大型临床试验和最终市场应用所必需的。随着针对 siRNA 的新靶标被确定,以及为优化其体内效率而合成的新型脂质,同时开发能够提高对这些复杂系统组装和稳定性的理解的生物物理方法至关重要。除了生物物理特性外,这些测定还需要可靠地设计、筛选、开发和优化制剂。因此,理化特性表征构成了开发有效的 siRNA 递送系统分析控制策略的基础。在这篇综述中,详细讨论了用于表征基于脂质的 siRNA 递送系统的分析技术。解释了这些理化特性表征技术和分析测定的重要性。展示了说明其在 siRNA 制剂开发和优化中应用的案例研究。